IDDF2020-ABS-0177 ERBB4 High Expression and Mutations in Gastric Cancer Present Opportunities for Clinical Landscape and Therapeutic Development

Zhao-lei Zeng,Jia-huan Lu,Qi Zhao,Yun Wang,Qi-nian Wu

DOI: https://doi.org/10.1136/gutjnl-2020-iddf.30

2020-01-01

Abstract:Background The human ERBB receptor tyrosine kinase family is deregulated in multiple cancer types either through amplification or mutations. The ERBB4 mutation of gastric cancer (GC) is listed as the top 2 alteration frequency, which was around 10%. Methods In order to understand the biological functions of ERBB4 wild-type (WT) and mutants, ERBB4 WT and its several hot spot mutants including R106H, R393W, S774G, and L798R were constructed into adenovirus with red fluorescent protein. We examined the ERBB4 WT and mutants for their roles in cell proliferation and metastasis and validated their sensitivity to tyrosine kinase inhibitors (TKIs) in vitro and in vivo. Results We found that the ERBB4 amplification and mutations played the oncogenic roles in GC, in which the ERBB4 mutations had more significant effects. ERBB4 overexpression and mutants increased the sensitivity of GC cells to TKIs in vitro and in vivo, especially the ERBB4 mutants had stronger effects. The mechanisms of ERBB4 oncogenic activities were dependent or independent on kinase active ERBB2. Conclusions This finding broadened the clinical application of TKIs targeted to ERBB2 or pan-ERBB, suggesting that they may provide therapeutic benefits to GC patients with ERBB4 overexpression or mutations. Moreover, ERBB4 is supposed to be a significant biomarker for GC treatment.